EGFR Amplification and PI3K Pathway Mutations Identify a Subset of Breast Cancers That Synergistically Respond to EGFR and PI3K Inhibition

The authors presented evidence of a patient subset with EGFR amplification and PI3Kinase pathway mutations in breast cancer which can be synergistically targeted by dual EGFR/PI3K inhibition.